Kim Jinsook, Kondratyev Alexei, Gale Karen
Interdisciplinary Program in Neuroscience, Georgetown University, W215 Research Building, 3970 Reservoir Road, N.W., Washington, DC 20057, USA.
J Pharmacol Exp Ther. 2007 Oct;323(1):165-73. doi: 10.1124/jpet.107.126250. Epub 2007 Jul 16.
The aim of this study was to test the potential neurotoxicity of three antiepileptic drugs (AEDs), carbamazepine (5H-dibenzepine-5-carboxamide), topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-d-fructopyranose sulfamate], and levetiracetam [2-(2-oxopyrrolidin-1-yl)butanamide], in the developing rat brain, when given alone or in combinations. The extent of cell death induced by AEDs was measured in several brain regions of rat pups (postnatal day 8) by terminal deoxynucleotidyl transferase dUTP nick-end labeling assay 24 h after drug treatment. Carbamazepine alone did not increase neurodegeneration when given in doses up to 50 mg/kg, but it induced significant cell death at 100 mg/kg. When combined with phenytoin, carbamazepine, 50 but not 25 mg/kg, significantly exacerbated phenytoin-induced cell death. Although topiramate (20-80 mg/kg) alone caused no neurodegeneration, all doses exacerbated phenytoin-induced neurodegeneration. Levetiracetam (250-1000 mg/kg) alone did not induce cell death, nor did it exacerbate phenytoin-induced neurodegeneration. Of the combinations examined, only that of levetiracetam (250 mg/kg) with carbamazepine (50 mg/kg) did not induce neurodegeneration. Our data underscore the importance of evaluating the safety of combinations of AEDs given during development and not merely extrapolating from the effects of exposure to single drugs. Although carbamazepine and topiramate alone did not induce neuronal death, both drugs exacerbated phenytoin-induced cell death. In contrast, because cotreatment with levetiracetam and carbamazepine did not enhance cell death in the developing brain, it may be possible to avoid proapoptotic effects, even in polytherapy, by choosing appropriate drugs. The latter drugs, as monotherapy or in combination, may be promising candidates for the treatment of women during pregnancy and for preterm and neonatal infants.
本研究的目的是测试三种抗癫痫药物(AEDs),即卡马西平(5H-二苯并氮杂䓬-5-甲酰胺)、托吡酯[2,3:4,5-双-O-(1-甲基亚乙基)-β-D-呋喃果糖磺酸酯]和左乙拉西坦[2-(2-氧代吡咯烷-1-基)丁酰胺]在发育中的大鼠脑中单独给药或联合给药时的潜在神经毒性。在药物治疗24小时后,通过末端脱氧核苷酸转移酶dUTP缺口末端标记法在幼鼠(出生后第8天)的几个脑区测量AEDs诱导的细胞死亡程度。单独给予卡马西平,剂量高达50mg/kg时不会增加神经退行性变,但在100mg/kg时会诱导显著的细胞死亡。当与苯妥英联合使用时,卡马西平50mg/kg而非25mg/kg会显著加剧苯妥英诱导的细胞死亡。虽然托吡酯(20 - 80mg/kg)单独使用不会引起神经退行性变,但所有剂量都会加剧苯妥英诱导的神经退行性变。左乙拉西坦(250 - 1000mg/kg)单独使用不会诱导细胞死亡,也不会加剧苯妥英诱导的神经退行性变。在所研究的联合用药中,只有左乙拉西坦(250mg/kg)与卡马西平(50mg/kg)的联合用药不会诱导神经退行性变。我们的数据强调了评估发育期间联合使用AEDs安全性的重要性,而不仅仅是从单一药物暴露的影响进行推断。虽然卡马西平和托吡酯单独使用不会诱导神经元死亡,但两种药物都会加剧苯妥英诱导的细胞死亡。相比之下,由于左乙拉西坦和卡马西平联合治疗不会增加发育中大脑的细胞死亡,通过选择合适的药物,即使在多药联合治疗中也可能避免促凋亡作用。后一种药物作为单一疗法或联合疗法,可能是治疗孕期妇女以及早产和新生儿的有前景的候选药物。